Search

Your search keyword '"Carradice, Daniel"' showing total 220 results
Start Over Author "Carradice, Daniel"
220 results on '"Carradice, Daniel"'

3. A Core Outcome Set for Intact Abdominal Aortic Aneurysm Repair

Author

Loftus, Ian, Azhar, Bilal, Bown, Matthew, Ulug, Pinar, Bicknell, Colin, Syed, Sadie, Allen, Louise, Pouncey, Anna, Haque, Adam, Hinchliffe, Robert, Staniszewska, Aleksandra, Tambyraja, Andrew, Carradice, Daniel, Bell, Rachel, Modarai, Bijan, Shaida, Nadeem, Trimarchi, Santi, Eilenberg, Wolf Hans, von Allmen, Regula, Lepidi, Sandro, Troisi, Nicola, Simonte, Gioele, Gallitto, Enrico, Melissano, Germano, Mezzetto, Luca, Tinelli, Giovanni, Fazzini, Stefano, Ferrer, Ciro, Franchin, Marco, Bertoglio, Luca, Bissacco, Daniele, Jangland, Eva, Ricco, Jean-Baptiste, Machin, Matthew, Wanhainen, Anders, D'Oria, Mario, Koelemaij, Mark, Kakkos, Stavros, Grima, Matthew Joe, and Powell, Janet T.

Published
2024
Full Text
View/download PDF

6. A Core Outcome Set for Intact Abdominal Aortic Aneurysm Repair

Author

Machin, Matthew, primary, Wanhainen, Anders, additional, D'Oria, Mario, additional, Koelemaij, Mark, additional, Kakkos, Stavros, additional, Grima, Matthew Joe, additional, Powell, Janet T., additional, Loftus, Ian, additional, Azhar, Bilal, additional, Bown, Matthew, additional, Ulug, Pinar, additional, Bicknell, Colin, additional, Syed, Sadie, additional, Allen, Louise, additional, Pouncey, Anna, additional, Haque, Adam, additional, Hinchliffe, Robert, additional, Staniszewska, Aleksandra, additional, Tambyraja, Andrew, additional, Carradice, Daniel, additional, Bell, Rachel, additional, Modarai, Bijan, additional, Shaida, Nadeem, additional, Trimarchi, Santi, additional, Eilenberg, Wolf Hans, additional, von Allmen, Regula, additional, Lepidi, Sandro, additional, Troisi, Nicola, additional, Simonte, Gioele, additional, Gallitto, Enrico, additional, Melissano, Germano, additional, Mezzetto, Luca, additional, Tinelli, Giovanni, additional, Fazzini, Stefano, additional, Ferrer, Ciro, additional, Franchin, Marco, additional, Bertoglio, Luca, additional, Bissacco, Daniele, additional, Jangland, Eva, additional, and Ricco, Jean-Baptiste, additional

Published
2024
Full Text
View/download PDF

10. Evaluating pharmacological THRomboprophylaxis in Individuals undergoing superficial endoVEnous treatment across NHS and private clinics in the UK: a multi-centre, assessor-blind, randomised controlled trial—THRIVE trial

Author

Machin, Matthew, primary, Whittley, Sarah, additional, Norrie, John, additional, Burgess, Laura, additional, Hunt, Beverley J, additional, Bolton, Layla, additional, Shalhoub, Joseph, additional, Everington, Tamara, additional, Gohel, Manjit, additional, Whiteley, Mark S, additional, Rogers, Steven, additional, Onida, Sarah, additional, Turner, Benedict, additional, Nandhra, Sandip, additional, Lawton, Rebecca, additional, Stephens-Boal, Annya, additional, Singer, Carolyn, additional, Dunbar, Joanne, additional, Carradice, Daniel, additional, and Davies, A H, additional

Published
2024
Full Text
View/download PDF

12. Tailored risk assessment and forecasting in intermittent claudication

Author

Ravindhran, Bharadhwaj, primary, Prosser, Jonathon, additional, Lim, Arthur, additional, Mishra, Bhupesh, additional, Lathan, Ross, additional, Hitchman, Louise H, additional, Smith, George E, additional, Carradice, Daniel, additional, Chetter, Ian C, additional, Thakker, Dhaval, additional, and Pymer, Sean, additional

Published
2024
Full Text
View/download PDF

14. THRomboprophylaxis in Individuals undergoing superficial endoVEnous treatment: a multi-centre, assessor blind, randomised controlled trial (THRIVE trial)

Author

Machin, Matthew, primary, Whittley, Sarah, additional, Norrie, John, additional, Burgess, Laura, additional, Hunt, Beverley J., additional, Bolton Saghdaoui, Layla, additional, Shalhoub, Joseph, additional, Everington, Tamara, additional, Gohel, Manjit, additional, Whiteley, Mark, additional, Rogers, Steven, additional, Onida, Sarah, additional, Turner, Benedict, additional, Nandhra, Sandip, additional, Lawton, Rebecca, additional, Stephens-Boal, Annya, additional, Singer, Carolyn, additional, Dunbar, Joanne, additional, Davies, Alun Huw, additional, and Carradice, Daniel, additional

Published
2023
Full Text
View/download PDF

19. The SHOCC Study: SHOCkwave Lithotripsy for Patients with Peripheral Arterial Disease

Author

Lopez-Pena, Gabriel, primary, Finch, Sarah, additional, Messeder, Sarah Jane, additional, Katsogridakis, Emmanuel, additional, Vijaynagar, Badri, additional, Davies, Robert, additional, Bown, Matthew, additional, Musto, Liam, additional, Carradice, Daniel, additional, Lakshminarayan, Raghu, additional, Callis, Ann-Marie, additional, Hitchman, Louise, additional, Sohrabi, Soroush, additional, Rees, Owen, additional, Thulasidasan, Narayanan, additional, Benton, Lily, additional, Miller, Christopher, additional, Coughlin, Patrick, additional, Twine, Christopher, additional, Mezes, Peter, additional, Lechareas, Symeon, additional, Moxey, Paul, additional, Chun, Joo-Young, additional, and Saratzis, Athanasios, additional

Published
2023
Full Text
View/download PDF

20. Minimally invasive treatment of venous insufficiency using endovenous laser ablation

Author

Carradice, Daniel and Chetter, Ian

Subjects
616.14, Medicine
Abstract

Background: Venous insufficiency is very common and causes significant quality of life (QoL) impairment. Conventional open surgery featuring junction ligation, stripping of the axial vein and phlebectomy is known to offer significant benefits over conservative management; resulting in improved QoL. Additionally this treatment has been shown to be highly cost-effective. Despite these advantages, surgery is associated with significant post-operative morbidity; in the form of pain and immobility, even in the absence of complications. Additionally, in the long term; high recurrence rates have marred these promising early results, eventually returning patients to their pre-operative state. Unsurprisingly recurrence is unpopular with patients and patient satisfaction has been observed to be disappointingly low. At the end of the 20th century, new minimally invasive endovenous interventions were developed. Rapidly gaining popularity; it was hoped that they could address some of the limitations of surgery. Following initial cases series; the endothermal technique of endovenous laser ablation (EVLA) appeared to have the highest technical efficacy with a good safety record. Objectives: Three studies were performed with the aim of perfecting the ablative procedure and evaluating it against the gold standard of conventional surgery. Study 1 was designed to establish the optimal management of saphenous tributaries and perforators following ablation of the saphenous axis. Study 2 was designed to directly compare the outcomes of EVLA with surgery to establish whether EVLA can match the effectiveness of surgery, whilst addressing its limitations. Study 3 was designed to explore the association between the magnitude of energy delivered during EVLA, procedural safety and periprocedural morbidity; in the context of evidence suggesting lower recanalisation rates following more aggressive use of laser energy. Methods: Studies 1 and 2 were randomised clinical trials. Participants had primary, symptomatic, unilateral venous insufficiency, with isolated saphenofemoral junction incompetence, leading to reflux into the great saphenous vein (GSV). Study 1 randomised 50 patients to EVLA alone (Control) or EVLA with concomitant ambulatory phlebectomies (EVLTAP). Study 2 randomised 280 patients equally into groups receiving either surgery or EVLA. Outcomes were: QoL, Venous Clinical Severity Score (VCSS), technical success, requirement for secondary procedures, pain scores, time taken to return to normal function, recurrent varicose veins on clinical examination, patterns of reflux on duplex ultrasound examination, and the effect of recurrence on quality of life. Assessments were at 1, 6, 12 and 52 weeks after the procedure. Study 3 used linear and logistic regression models to study the effect of energy delivery on outcome. The models controlled for age, gender, BMI, pre-operative QoL and vein dimension. The outcomes were QoL, complications, recovery time, pain scores and analgesia requirements. The sample size calculation established that 115 patients would be required to detect any significant relationship. Results: Study 1: EVLTAP took longer, but significantly decreased the requirement for subsequent interventions. There was no impairment in immediate post-procedural pain or QoL with EVLTAP. Median (IQR) Venous Clinical Severity Score (VCSS) at 3 months was lower (better) for EVLTAP than for Control (0 (0-1) versus 2 (0-2); P < 0.001), with lower (better) disease specific QoL (Aberdeen Varicose Vein Questionnaire (AVVQ) scores) at 6 weeks (7.9 (4.1-10.7) versus 13.5 (10.9-18.1); P < 0.001) and 3 months (2.0 (0.4-7.7) versus 9.6 (2.2-13.8); P = 0.015). At 1 year, there were no differences in VCSS or AVVQ scores. Study 2: Both groups had significant improvements in VCSS after treatment (P < 0.001), which resulted in improved disease-specific QoL (AVVQ, P < 0.001) and quality-adjusted life year (QALY) gain (P < 0.001). The pain and disability following surgery impaired normal function, with a significant decline in five of eight SF-36 domains (P < 0.001 to P = 0.029). Periprocedural QoL was relatively preserved following EVLA, leading to a significant difference between the two treatments in pain scores (P < 0.001), six of eight SF-36 domains (P = 0.004 to P = 0.049) and QALYs (P = 0.003). As a result, surgical patients took longer to return to work and normal activity (14 versus 3 days; P < 0.001). Complications were rare. Initial technical success was greater following EVLA: 99.3 versus 92.4% (P = 0.005). Surgical failures related mainly to an inability to strip the above-knee GSV. The clinical recurrence rate at 1 year was lower after EVLA: 4.0 versus 20.4% (P < 0.001). The number of patients needed to treat with EVLA rather than surgery to avoid one recurrence at 1 year was 6.3 (95 per cent confidence interval 4.0 to 12.5). 12 of 23 surgical recurrences were related to an incompetent below-knee GSV and ten to neovascularisation. Of five recurrences after EVLA, two were related to neoreflux in the groin tributaries and one to recanalisation. Clinical recurrence was associated with worse QoL (AVVQ scores) (P < 0.001). Study 3: 232 patients were included. The mean (range) age was 50 (18-83) years. 63% were women. The mean (range) energy delivery was 89.8 (44.5-158.4) Jcm-1. There was no significant effect on any outcome related to increasing energy delivery. Conclusions: Concomitant phlebectomy with EVLA prolonged the procedure, but reduced the need for secondary procedures and significantly improved quality of life and the severity of venous disease. This supports a recommendation that phlebectomy is performed routinely in conjunction with EVLA. EVLA was as effective as surgery for varicose veins, but importantly had lower periprocedural morbidity as evidenced by less negative impact on early post-intervention QoL and furthermore clinical recurrence rates were also significantly lower than observed following conventional surgery. This suggests that EVLA with phlebectomy is superior to conventional surgery in the management of primary superficial venous insufficiency. Study 3 clearly confirms that EVLA is a safe procedure and that for the range of energies studied, there was no evidence demonstrating an increase in complication rates or the periprocedural morbidity of EVLA. These findings support the adoption of EVLA and concomitant phlebectomy as the gold standard treatment for primary superficial venous insufficiency.

Published
2011

24. Completion of Supervised Exercise Therapy Improves Outcomes for Patients with Intermittent Claudication: Propensity Score-matched Analysis of 7-year Outcomes

Author

Ravindhran, Bharadhwaj, primary, Lim, Arthur, additional, Walshaw, Josephine, additional, Kurian, Thomas, additional, Sidapra, Misha, additional, Lathan, Ross, additional, Hitchman, Louise H., additional, Mohamed, Abduraheem, additional, Carradice, Daniel, additional, Smith, George, additional, Chetter, Ian, additional, and Pymer, Sean, additional

Published
2023
Full Text
View/download PDF

28. Umbrella review and meta-analysis of reconstructed individual patient data of mortality following conventional endovascular and open surgical repair of infrarenal abdominal aortic aneurysm

Author

Veličković, Vladica M., primary, Carradice, Daniel, additional, Boyle, Jonathan R, additional, Hamady, Mohamad, additional, Cleveland, Trevor, additional, Neequaye, Simon, additional, Ignjatović, Aleksandra, additional, Bogdanović, Dragana, additional, Savovic, Jelena, additional, and Siebert, Uwe, additional

Published
2023
Full Text
View/download PDF

35. Extracorporeal shockwave therapy compared with standard care for diabetic foot ulcer healing: An updated systematic review.

Author

Hitchman, Louise, Totty, Joshua, Smith, George E., Carradice, Daniel, Twiddy, Maureen, Iglesias, Cynthia, Russell, David, and Chetter, Ian C.

Subjects
DIABETES complications, TREATMENT of diabetic foot, WOUND healing, SYSTEMATIC reviews, EVIDENCE-based medicine, TREATMENT effectiveness, COMPARATIVE studies, ULTRASONIC therapy, DOSE-response relationship in biochemistry, EVALUATION
Abstract

Emerging evidence suggests that extracorporeal shockwave therapy (ESWT) may improve time to DFU healing. The aim of this review was to appraise the evidence on role of ESWT in DFU healing and impact of different ESWT doses. Databases were searched for trials comparing ESWT plus standard care to standard care alone in participants with DFUs. Search results were reviewed by two independent reviewers. The Cochrane Risk of Bias 2 tool and GRADE approach was used to assess bias and certainty. The primary outcome was time to healing. The search identified 345 papers after duplicates removed. Six trials consisting of 471 participants were included. There was unclear or high risk of bias across all domains. Time to ulcer healing was probably shorter in patients treated with ESWT compared with standard ulcer care alone (GRADE: low certainty). Patients treated with ESWT were more likely to heal at 20 weeks post‐ESWT compared with those treated with standard ulcer care alone (GRADE: low certainty). There was significant heterogeneity. ESWT remains a promising new treatment but the translation into routine clinical practice is still limited by the low certainty of evidence surrounding its effectiveness, case selection and optimum dose. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Clinical outcomes following mechanochemical ablation of superficial venous incompetence compared with endothermal ablation: meta-analysis.

Author

M. Lim, Arthur J., Mohamed, Abduraheem H., Hitchman, Louise H., Lathan, Ross, Ravindhran, Bharadhwaj, Sidapra, Misha M., Smith, George, Chetter, Ian C., and Carradice, Daniel

Subjects
VARICOSE veins, TREATMENT effectiveness, THROMBOEMBOLISM, QUALITY of life, ANESTHESIA
Abstract

Background: Mechanochemical ablation (MOCA) is an alternative method to endovenous thermal ablation (EVTA) for the treatment of superficial venous incompetence that does not require tumescent anaesthesia. The aim of this study was to compare the outcomes from RCTs of MOCA versus EVTA. Methods: A search was conducted in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL). Metaanalysis inclusion was restricted to RCTs comparing MOCA against EVTA. Outcomes included anatomical occlusion rate, diseasespecific quality of life using the Aberdeen Varicose Vein Questionnaire, procedural and postprocedural pain, and rates of venous thromboembolism. Results: Four RCTs were included in the meta-analysis comprising 654 patients. The anatomical occlusion rate at 1 year was lower after MOCA than EVTA (risk ratio 0.85, 95 per cent c.i. 0.78 to 0.91; P < 0.001). No significant differences were detected in procedural pain (mean difference -3.25, -14.25 to 7.74; P = 0.560) or postprocedural pain (mean difference -0.63, -2.15 to 0.89; P = 0.420). There were no significant differences in Aberdeen Varicose Vein Questionnaire score at 1 year (mean difference 0.06, -0.50 to 0.62; P = 0.830) or in incidence of venous thromboembolism (risk ratio 0.72, 95 per cent c.i. 0.14 to 3.61; P = 0.690). Conclusion: The rate of successful anatomical occlusion after MOCA is significantly lower than that after EVTA, but there is no difference in procedural and postprocedural pain between the two interventions. Long-term data are required to assess the impact of the reduced vein occlusion rate on clinical outcomes such as quality of life and reintervention. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. Provision of NICE-recommended varicose vein treatment in the NHS.

Author

Hitchman, Louise H., Mohamed, Abduraheem, Smith, George E., Pymer, Sean, Chetter, Ian C., Forsyth, James, and Carradice, Daniel

Subjects
VARICOSE veins, HOSPITAL statistics, PATIENT compliance, HEALTH services accessibility, CARE of people
Abstract

Background: Standardization of access to treatment and compliance with clinical guidelines are important to ensure the delivery of high-quality care to people with varicose veins. In the National Health Service (NHS) in England, commissioning of care for people with varicose veins is performed by Clinical Commissioning Groups (CCGs) and clinical guidelines have been developed by the National Institute for Health and Care Excellence (NICE CG168). The Evidence-Based Intervention (EBI) programme was introduced in the NHS with the aim of improving care quality and supporting implementation of NICE CG168. The aim of this study was to assess access to varicose vein treatments in the NHS and the impact of EBI. Methods: CCG policies for the delivery of varicose vein treatments in the NHS in England were obtained from 2017 (before EBI introduction) and 2019 (after EBI introduction) and categorized by two independent reviewers into levels of compliance with NICE CG168. Hospital Episode Statistics data were compared with the NICE commissioning model predictions. A quality-adjusted life-year was valued at £20 000 (Euro 23 000 15 November 2022). Results: Despite the introduction of the EBI programme, CCG compliance with NICE CG168 fell from 34.0 per cent (64 of 191) to 29.0 per cent (55 of 191). Some 33.0 per cent of CCG policies (63 of 191) became less compliant and only 7.3 per cent (14 of 191) changed to become fully compliant. Overall, 66.5 per cent of CCGs (127 of 191) provided less than the recommended intervention rate before EBI and this increased to 73.3 per cent (140 of191) after EBI. The overall proportion of patients estimated to require treatment annually who received treatment fell from 44.0 to 37.0 per cent. The associated estimated loss in net health benefit was between £164 and 174 million (Euro 188 million and 199 million 15 November 2022) over 3 years. A compliant policy was associated with a higher intervention rate; however, commissioning policy was associated with only 16.8 per cent of the variation in intervention rate (R2=0.168, P<0.001). Conclusion: Many local varicose vein commissioning policies in the NHS are not compliant with NICE CG168. More than half of patients who should be offered varicose vein treatment are not receiving it, and there is widespread geographical variation. The EBI programme has not been associated with any improvement in commissioning or access to varicose vein treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

42. Molecular mechanisms of action of negative pressure wound therapy: a systematic review.

Author

Ravindhran, Bharadhwaj, Schafer, Nicole, Howitt, Annabel, Carradice, Daniel, Smith, George, and Chetter, Ian

Subjects
NEGATIVE-pressure wound therapy, CLINICAL trial registries, GROWTH factors, WOUND care, GENE expression
Abstract

Negative pressure wound therapy (NPWT) has significantly advanced wound care and continues to find new applications. Its effects at a molecular level however, remain a subject of debate. The aim of this systematic review is to summarize the current evidence regarding the molecular mechanisms of action of NPWT. Medline, Embase, EBSCO databases and clinical trial registries were searched from inception to January 2023. Clinical studies, animal models or in-vitro studies that quantitatively or semi-quantitatively evaluated the influence of NPWT on growth factors, cytokine or gene-expression in the circulation or wound-bed were included. Risk of Bias assessment was performed using the RoBANS tool for non-randomized studies, the COCHRANE's Risk of Bias 2(ROB-2) tool for randomized clinical studies, OHAT tool for in-vitro studies or the SYRCLE tool for animal model studies. A descriptive summary was collated and the aggregated data is presented as a narrative synthesis. This review included 19 clinical studies, 11 animal studies and 3 in-vitro studies. The effects of NPWT on 43 biomarkers and 17 gene expressions were studied across included studies. NPWT stimulates modulation of numerous local and circulating cytokines and growth factor expressions to promote an anti-inflammatory profile. This is most likely achieved by downregulation of TNF α , upregulation of VEGF, TGF- β and fibronectin. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

44. sj-pdf-1-phl-10.1177_0268355520936420 - Supplemental material for Reducing the risk of venous thromboembolism following superficial endovenous treatment: A UK and Republic of Ireland consensus study

Author

Nikesh Dattani, Shalhoub, Joseph, Sandip Nandhra, Lane, Tristan, Abdulsalam Abu-Own, Elbasty, Ahmed, Jones, Aled, Duncan, Andrew, Garnham, Andrew, Ankur Thapar, Murray, Anna, Anzar Baig, Saratzis, Athanasios, Sharif, Atif, Huasen, Bella, Dawkins, Claire, Nesbitt, Craig, Carradice, Daniel, Morrow, Darren, Bosanquet, David, Kavanagh, Eamon, Shaikh, Faisal, Gosi, Gergely, Ambler, Graeme, Fulton, Gregory, Gurdas Singh, Travers, Hannah, Moore, Hayley, Olivier, James, Hitchman, Louise, O’Donohoe, Martin, Popplewell, Matthew, Mekki Medani, Jenkins, Michael, Mingzheng A Goh, Lyons, Oliver, McBride, Olivia, Moxey, Paul, Stather, Philip, Burns, Phillipa, Forsythe, Rachel, Sam, Rachel, Brar, Ranjeet, Brightwell, Robert, Benson, Ruth, Onida, Sarah, Sharath Paravastu, Lambracos, Simon, Vallabhaneni, Srinivasa R, Walsh, Stewart, Tasleem Aktar, Moloney, Tony, Mzimba, Zola, and Nyamekye, Isaac

Subjects
Cardiology
Abstract

Supplemental material, sj-pdf-1-phl-10.1177_0268355520936420 for Reducing the risk of venous thromboembolism following superficial endovenous treatment: A UK and Republic of Ireland consensus study by Nikesh Dattani, Joseph Shalhoub, Sandip Nandhra, Tristan Lane, Abdulsalam Abu-Own, Ahmed Elbasty, Aled Jones, Andrew Duncan, Andrew Garnham, Ankur Thapar, Anna Murray, Anzar Baig, Athanasios Saratzis, Atif Sharif, Bella Huasen, Claire Dawkins, Craig Nesbitt, Daniel Carradice, Darren Morrow, David Bosanquet, Eamon Kavanagh, Faisal Shaikh, Gergely Gosi, Graeme Ambler, Gregory Fulton, Gurdas Singh, Hannah Travers, Hayley Moore, James Olivier, Louise Hitchman, Martin O’Donohoe, Matthew Popplewell, Mekki Medani, Michael Jenkins, Mingzheng A Goh, Oliver Lyons, Olivia McBride, Paul Moxey, Philip Stather, Phillipa Burns, Rachel Forsythe, Rachel Sam, Ranjeet Brar, Robert Brightwell, Ruth Benson, Sarah Onida, Sharath Paravastu, Simon Lambracos, Srinivasa R Vallabhaneni, Stewart Walsh, Tasleem Aktar, Tony Moloney, Zola Mzimba and Isaac Nyamekye in Phlebology

Published
2020
Full Text
View/download PDF

48. Reducing the risk of venous thromboembolism following superficial endovenous treatment: A UK and Republic of Ireland consensus study

Author

Dattani, Nikesh, primary, Shalhoub, Joseph, additional, Nandhra, Sandip, additional, Lane, Tristan, additional, Abu-Own, Abdulsalam, additional, Elbasty, Ahmed, additional, Jones, Aled, additional, Duncan, Andrew, additional, Garnham, Andrew, additional, Thapar, Ankur, additional, Murray, Anna, additional, Baig, Anzar, additional, Saratzis, Athanasios, additional, Sharif, Atif, additional, Huasen, Bella, additional, Dawkins, Claire, additional, Nesbitt, Craig, additional, Carradice, Daniel, additional, Morrow, Darren, additional, Bosanquet, David, additional, Kavanagh, Eamon, additional, Shaikh, Faisal, additional, Gosi, Gergely, additional, Ambler, Graeme, additional, Fulton, Gregory, additional, Singh, Gurdas, additional, Travers, Hannah, additional, Moore, Hayley, additional, Olivier, James, additional, Hitchman, Louise, additional, O’Donohoe, Martin, additional, Popplewell, Matthew, additional, Medani, Mekki, additional, Jenkins, Michael, additional, Goh, Mingzheng A, additional, Lyons, Oliver, additional, McBride, Olivia, additional, Moxey, Paul, additional, Stather, Philip, additional, Burns, Phillipa, additional, Forsythe, Rachel, additional, Sam, Rachel, additional, Brar, Ranjeet, additional, Brightwell, Robert, additional, Benson, Ruth, additional, Onida, Sarah, additional, Paravastu, Sharath, additional, Lambracos, Simon, additional, Vallabhaneni, Srinivasa R, additional, Walsh, Stewart, additional, Aktar, Tasleem, additional, Moloney, Tony, additional, Mzimba, Zola, additional, and Nyamekye, Isaac, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results